Venn Life Sciences Holdings (VENN)

 

VENN Share PerformanceMore

52 week high30.300 03/08/16
52 week low15.110 28/02/17
52 week change -9.000 (-35.64%)
4 week volume2,277,933 02/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Result of AGM

RNS Number: 4690D Venn Life Sciences Holdings PLC 26 April 2017 26 April 2017 Venn Life Sciences Holdings Plc ("Venn" or the "Company") Result of Annual General Meeting Venn Life Sciences Holdings plc (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to phar...

Proposed amendment to AGM resolution

RNS Number: 3003D Venn Life Sciences Holdings PLC 25 April 2017 25 April 2017 Venn Life Sciences Holdings Plc ("Venn" or the "Company") AGM update Proposed amendment to resolution to be considered at AGM Venn Life Sciences Holdings plc (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial manag...

Integumen IPO

RNS Number: 5942B Venn Life Sciences Holdings PLC 05 April 2017 5 April 2017 Venn Life Sciences Holdings Plc ("Venn" or the "Company") IPO of Integumen plc Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology a...

Enterprise Securities Market Notice

RNS Number: 9358A Irish Stock Exchange 04 April 2017 REPORT OF THE BOARD OF THE IRISH STOCK EXCHANGE Irish Stock Exchange 28 Anglesea Street DUBLIN 2 4 th April 2017 ESM ADMISSION NOTICE The Board of the Irish Stock Exchange approves admission of the under-mentioned security to trading on the Enterprise Securities Market. Venn L...

Annual Financial Report & Notice of AGM

RNS Number: 1795B Venn Life Sciences Holdings PLC 31 March 2017 31 March 2017 Venn Life Sciences Holdings Plc ("Venn" or the "Company") Posting of Annual Report & Notice of AGM Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharm...

Issue of Equity

RNS Number: 9163A Venn Life Sciences Holdings PLC 29 March 2017 29 March 2017 Venn Life Sciences Holdings Plc ("Venn" or the "Company") Issue of Equity Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and...

Venn Life Sciences swings to FY pretax loss

Venn Life Sciences has swung to a FY pretax loss after what it described as another strong year. "We have started 2017 wit...

Final Results

RNS Number: 1499A Venn Life Sciences Holdings PLC 22 March 2017 22 March 2017 Venn Life Sciences Holdings Plc ("Venn" or the "Company") Final Results for the year ended 31 December 2016 Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to...

Equity Research (VENN)

Venn Life Sciences Holdings plc
31/03/2017
Venn’s full year results last week highlighted some of the growing pains associated with high growth companies and bedding down significant acquisitions. The impressive 57% top line growth was...
Venn Life Sciences Holdings plc
22/03/2017
The growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients has...
Venn Life Sciences Holdings plc
08/11/2016
The growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, has...

Latest discussion posts More

  • New update from Davy Stockbrokers

    Davy Stockbrokers issued a positive update on VENN last week. It's client-only, but there's a summary ...
    19-Apr-2017
    gretel
  • Hybridan's new note

    FYI here's Hybridan's summary and new forecasts from 2 weeks ago: "Continuing growth not recognised in current price. Underlying fundamentals remain strong. ?m 2015A ...
    18-Apr-2017
    gretel
  • Re: 50% of m/cap in cash/liquid assets

    In summary then, VENN now have against a #10m m/cap: - #3m of cash - #1.9m of Integumen shares at the current 4.5p bid price - a business turning over 18m euros and ...
    5-Apr-2017
    gretel

Users' HoldingsMore

Users who hold Venn Life Sciences Holdings also hold..
APC TECHNOLOGY21%
ROCKHOPPER15%
BT GROUP15%
GLAXOSMITHKLINE15%
SERICA15%

Codes & Symbols

ISINGB00B9275X97
SymbolsVENN, LSE:VENN, VENN.L, VENN:LN, LON:VENN, XLON:VENN